RESUMO
Aggressive intravenous and oral dual antiplatelet therapy has established primary percutaneous coronary intervention (PCI) as the standard of care for acute myocardial infarction. Clopidogrel is currently the thienopyridine of choice for dual antiplatelet therapy in patients treated with PCI. The dose regime and duration of therapy of clopidogrel has undergone multiple refinements. Recently, 2 novel third generation oral inhibitors of P2Y12 receptors, prasugrel and ticagrelor, have undergone clinical evaluation with promising results. This article is a non-exhaustive review of the literature, concentrating on the role of current and novel oral antiplatelet agents for acute myocardial infarction particularly highlighting the limitations and issues associated with clopidogrel use.
Assuntos
Humanos , Adenosina , Angioplastia Coronária com Balão , Quimioterapia Combinada , Eletrocardiografia , Infarto do Miocárdio , Tratamento Farmacológico , Cirurgia Geral , Piperazinas , Inibidores da Agregação Plaquetária , Cloridrato de Prasugrel , Tiofenos , TiclopidinaRESUMO
A 66-year-old male presented with posterior myocardial infarction and painless rectal bleeding. He was treated for acute coronary event but despite extensive investigations the cause of his lower gastrointestinal bleeding remained elusive. Patient died 5 days after admission. Postmortem examination showed evidence of severe atherosclerosis and thrombosis in branches of abdominal aorta leading to bowel ischemia with multiple perforations and necrosis. The findings are consistent with the diagnosis of necrotizing enterocolitis [NEC]. Main factors responsible for pathogenesis of NEC are bowel ischemia and bacterial infection. It can be classified into 3 stages according to the level of severity. Treatment ranges from mainly supportive in the initial phase to surgery in severe cases